RS50083B - N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije - Google Patents

N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije

Info

Publication number
RS50083B
RS50083B YUP-603/01A YUP60301A RS50083B RS 50083 B RS50083 B RS 50083B YU P60301 A YUP60301 A YU P60301A RS 50083 B RS50083 B RS 50083B
Authority
RS
Serbia
Prior art keywords
piperidinyl
propoxy
pyridine
hydroxy
oxide
Prior art date
Application number
YUP-603/01A
Other languages
English (en)
Inventor
Laszlo Urogdi
Katalin Biro
Jeno Szilbereky
Ede Marvanyos
Laszlo Koranyi
Mihaly Barabas
Magdolna Torok
Zita Csakai
Zoltan Nagy
Maria Kurthy
Karoly Nagy
Tamas Mogyorosi
Andras Komaromi
Mihalyne Kardos
Melinda Nagy
Original Assignee
Biorex Kutato Es Fejleszto Rt.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Es Fejleszto Rt., filed Critical Biorex Kutato Es Fejleszto Rt.,
Publication of YU60301A publication Critical patent/YU60301A/sh
Publication of RS50083B publication Critical patent/RS50083B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

N-{2-hidroksi-3-(1-piperidinil)-propoksi}-piridin-1-oksid-3-karboksiimidoil hlorid, njegovi stereoizomeri, i adicione soli sa kiselinama. Prijava sadrži još 3 patentna zahteva.
YUP-603/01A 1999-02-26 2000-02-24 N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije RS50083B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Publications (2)

Publication Number Publication Date
YU60301A YU60301A (sh) 2004-05-12
RS50083B true RS50083B (sr) 2009-01-22

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-603/01A RS50083B (sr) 1999-02-26 2000-02-24 N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije

Country Status (27)

Country Link
US (1) US6649628B1 (sr)
EP (1) EP1163224B1 (sr)
JP (1) JP4689838B2 (sr)
KR (1) KR100676124B1 (sr)
AT (1) ATE237590T1 (sr)
AU (1) AU779096B2 (sr)
BG (1) BG65178B1 (sr)
BR (1) BR0008969A (sr)
CA (1) CA2360451C (sr)
CZ (1) CZ297386B6 (sr)
DE (1) DE60002187T2 (sr)
DK (1) DK1163224T3 (sr)
EE (1) EE04961B1 (sr)
ES (1) ES2193055T3 (sr)
HR (1) HRP20010584B1 (sr)
HU (1) HUP9900475D0 (sr)
IL (2) IL144866A0 (sr)
NO (1) NO319793B1 (sr)
PL (1) PL197692B1 (sr)
PT (1) PT1163224E (sr)
RS (1) RS50083B (sr)
RU (1) RU2250901C2 (sr)
SI (1) SI1163224T1 (sr)
SK (1) SK287063B6 (sr)
UA (1) UA72495C2 (sr)
WO (1) WO2000050403A1 (sr)
ZA (1) ZA200106488B (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
IL162941A0 (en) 2002-01-11 2005-11-20 Biorex Kutato Fejlesztoe Kft Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
JP2010150243A (ja) * 2008-11-18 2010-07-08 Santen Pharmaceut Co Ltd ピリジン−３−カルバルデヒドｏ−（ピペリジン−１−イル−プロピル）−オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
ES2753169T3 (es) 2010-11-30 2020-04-07 Orphazyme As Procedimientos para aumentar la actividad intracelular de Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
EP2892540B1 (en) * 2012-09-06 2018-07-25 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
DK2896269T4 (da) 2012-09-14 2020-08-31 Saint Gobain Rude med et elektrisk forbindelseselement
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
HUE054957T2 (hu) * 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
US20200085812A1 (en) 2017-05-24 2020-03-19 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
WO2019229078A1 (en) 2018-05-28 2019-12-05 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
KR20230035586A (ko) 2020-06-24 2023-03-14 켐팜 덴마크 에이/에스 고셔병을 치료하기 위한 아리모클로몰
WO2022106614A1 (en) * 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
JP2024502304A (ja) 2020-12-24 2024-01-18 ゼブラ デンマーク エー／エス Ｅｒ型ミスセンス変異を有する患者におけるニーマンピック病ｃ型の治療用アリモクロモル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
NO20014103L (no) 2001-10-22
PL350915A1 (en) 2003-02-10
US6649628B1 (en) 2003-11-18
EE04961B1 (et) 2008-02-15
JP4689838B2 (ja) 2011-05-25
CA2360451C (en) 2011-01-04
YU60301A (sh) 2004-05-12
BG65178B1 (bg) 2007-05-31
SK287063B6 (sk) 2009-10-07
AU779096B2 (en) 2005-01-06
BR0008969A (pt) 2001-11-27
UA72495C2 (uk) 2005-03-15
KR20010102410A (ko) 2001-11-15
SI1163224T1 (en) 2003-08-31
HRP20010584B1 (en) 2010-08-31
EP1163224B1 (en) 2003-04-16
AU3182400A (en) 2000-09-14
CZ297386B6 (cs) 2006-11-15
NO20014103D0 (no) 2001-08-23
KR100676124B1 (ko) 2007-01-31
SK11582001A3 (sk) 2001-12-03
DK1163224T3 (da) 2003-08-04
EE200100447A (et) 2002-12-16
PL197692B1 (pl) 2008-04-30
CZ20013053A3 (cs) 2002-01-16
ATE237590T1 (de) 2003-05-15
NO319793B1 (no) 2005-09-12
RU2250901C2 (ru) 2005-04-27
HRP20010584A2 (en) 2002-08-31
DE60002187T2 (de) 2003-12-11
EP1163224A1 (en) 2001-12-19
HUP9900475D0 (en) 1999-04-28
PT1163224E (pt) 2003-07-31
CA2360451A1 (en) 2000-08-31
DE60002187D1 (de) 2003-05-22
ES2193055T3 (es) 2003-11-01
WO2000050403A1 (en) 2000-08-31
BG105837A (en) 2002-03-29
IL144866A (en) 2007-07-04
JP2002537384A (ja) 2002-11-05
IL144866A0 (en) 2002-06-30
ZA200106488B (en) 2002-08-07

Similar Documents

Publication Publication Date Title
RS50083B (sr) N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
EA199800667A1 (ru) Новые фенантридины
IT1307047B1 (it) Apparecchiatura per il trattamento umidificato dell'apnea da sonno.
DE59204339D1 (de) Derivate der 4-hydroxy-buttersäure.
YU41801A (sh) Derivati fenilglicina
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE495187T1 (de) Dalda-analoge und ihre verwendung
BR9913456A (pt) Micropartìculas
ATE402149T1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
DE60103927D1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
FI963511A0 (fi) Pakko-oireisten häiriöiden hoito 5-HT2-antagonisteilla
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
DE69814735D1 (de) Carbazolcarboxamide als 5-HT1F Agonisten
SE9902267D0 (sv) New compounds
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
PT1204659E (pt) Benzofuranos serotoninergicos
ATE280169T1 (de) Serotonerge benzothiophene
SE9902387D0 (sv) New pharmaceutically active compounds
SE9802538D0 (sv) New pharmaceutically active compounds
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE69715196T2 (de) Modifizierte form des hydrochlorids der r(-)-n-(4,4-di(-3-methylthien-2-yl)but-3-enyl)-nipecotinsäure